JP2015505555A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505555A5
JP2015505555A5 JP2014555310A JP2014555310A JP2015505555A5 JP 2015505555 A5 JP2015505555 A5 JP 2015505555A5 JP 2014555310 A JP2014555310 A JP 2014555310A JP 2014555310 A JP2014555310 A JP 2014555310A JP 2015505555 A5 JP2015505555 A5 JP 2015505555A5
Authority
JP
Japan
Prior art keywords
inhibition
cancer
compound
protein kinase
autoimmune disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555310A
Other languages
English (en)
Japanese (ja)
Other versions
JP6199316B2 (ja
JP2015505555A (ja
Filing date
Publication date
Priority claimed from GBGB1201566.5A external-priority patent/GB201201566D0/en
Application filed filed Critical
Publication of JP2015505555A publication Critical patent/JP2015505555A/ja
Publication of JP2015505555A5 publication Critical patent/JP2015505555A5/ja
Application granted granted Critical
Publication of JP6199316B2 publication Critical patent/JP6199316B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555310A 2012-01-30 2013-01-30 1H−ピロロ[2,3−b]ピリジン誘導体およびキナーゼ阻害剤としてのその使用 Expired - Fee Related JP6199316B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
GB1201566.5 2012-01-30
PCT/GB2013/050212 WO2013114113A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2015505555A JP2015505555A (ja) 2015-02-23
JP2015505555A5 true JP2015505555A5 (enExample) 2015-11-12
JP6199316B2 JP6199316B2 (ja) 2017-09-20

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555310A Expired - Fee Related JP6199316B2 (ja) 2012-01-30 2013-01-30 1H−ピロロ[2,3−b]ピリジン誘導体およびキナーゼ阻害剤としてのその使用

Country Status (21)

Country Link
US (3) US10000481B2 (enExample)
EP (1) EP2809670B1 (enExample)
JP (1) JP6199316B2 (enExample)
CN (4) CN104203948A (enExample)
AU (1) AU2013213954B2 (enExample)
BR (1) BR112014018795B1 (enExample)
CA (1) CA2862940C (enExample)
DK (1) DK2809670T3 (enExample)
EA (1) EA026657B1 (enExample)
ES (1) ES2637340T3 (enExample)
GB (1) GB201201566D0 (enExample)
HK (1) HK1200447A1 (enExample)
HU (1) HUE035332T2 (enExample)
IL (1) IL233595B (enExample)
IN (1) IN2014DN06104A (enExample)
MX (1) MX352927B (enExample)
NZ (1) NZ627361A (enExample)
PL (1) PL2809670T3 (enExample)
PT (1) PT2809670T (enExample)
WO (1) WO2013114113A1 (enExample)
ZA (1) ZA201405070B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
RU2635359C2 (ru) * 2012-04-23 2017-11-13 Дженентек Инк. Промежуточные химические соединения и способы получения соединений
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
DK3269370T3 (da) 2016-02-23 2020-04-06 Taiho Pharmaceutical Co Ltd Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf
EP3674325A4 (en) 2017-08-21 2021-11-03 Taiho Pharmaceutical Co., Ltd. FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ifm Due有限公司 用於治療與sting活性相關之病況的化合物及組合物
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
KR20220042159A (ko) 2019-08-01 2022-04-04 인테그랄 바이오사이언스 피브이티. 엘티디. 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
JP2023540674A (ja) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
PY2157405A (es) * 2020-07-15 2022-04-22 Ifm Due Inc Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
WO2023137034A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
AU2004293026B2 (en) * 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
WO2009089352A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
JP5386508B2 (ja) * 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
CA2726114A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
KR20120055608A (ko) * 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 신규한 이환 우레아 화합물
EP2571361A4 (en) * 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Similar Documents

Publication Publication Date Title
IL259253B (en) Drowsiness onset detection
JP2017537928A5 (enExample)
IL244748B (en) Methods and processes for non-invasive assessment of genetic variations
JP2015125255A5 (enExample)
EP2951139A4 (en) SYNTHESIS FROM 1,1,2,3-TETRACHLORPROPENE
JP2015503422A5 (enExample)
IL242056B (en) Registration maps using intra-cardiac signals
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
EP3730050C0 (en) DETERMINATION OF REFERENCE ANNOTATION TIME FROM MULTI-CHANNEL ELECTROCARDIOGRAM SIGNALS
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
EP2971207A4 (en) PREPARATION OF ALUMINUM SCANDIUM ALLOYS
HUE043206T2 (hu) Kortisztatin-analógok gyulladásos és/vagy immunbetegségek kezelésére
EP3008124A4 (en) STRENGTH COMPOSITIONS AND USE THEREOF
PL3487491T3 (pl) Kompozycje do zwiększenia aktywności mózgu
EP3506254A4 (en) SOUNDPROOF STRUCTURE
PL3414361T3 (pl) Grafen i wytwarzanie grafenu
IL252886A0 (en) Processes and systems for the catalytic production of wax ester derivatives
PL3226888T3 (pl) Podawanie selektywnego transsygnałowego inhibitora IL-6
IL263221B (en) Epicardial mapping
WO2015066485A3 (en) Mitochondrial disease genetic diagnostics
ES1117305Y (es) Despertador para activar la incorporación del usuario.
MacKay The engine of memory
JP2017516883A5 (enExample)
IL243550A0 (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
Gravotta THE UNADVERTISED USES OF DRUGS